- Home
- Programs and Groups
- Shared Resources
- Faculty
- Clinical Trials
- Tumor Registry
- Education
- About DCI
Quick Links
Breadcrumbs Navigation
Home > Clinical Trials > A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in Subjects with Surgically Resected Pancreatic CancerA Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in Subjects with Surgically Resected Pancreatic Cancer
Category: Gastrointestinal Cancers - Colorectal cancers and cancers of the stomach, esophagus and other digestive organs (Adult)
Phase: Phase III
Principal Investigator: Michael Morse
Phone: 919-668-1861
Sponsor: Commercial / Industry (for-profit group) initiated
ID Number: 00022100
NCT Number: NCT01072981
